United Therapeutics (UTHR) Tops Q2 EPS by 76c, Sales Easily Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
United Therapeutics Corporation Reports Second Quarter 2017 Financial Results
July 27, 2017 6:00 AM EDTSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 27, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2017.
"Our second quarter total net revenues reached $445 million, our highest quarterly net revenue level ever," said Martine Rothblatt, Ph.D., United Therapeutics Chairman and Chief Executive Officer. "We continue to believe that Orenitram is well-positioned given the large and growing number of pulmonary arterial hypertension (PAH) patients in need of a true prostacyclin analogue therapy following their use... More
